<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="HandheldFriendly" content="true">

<title>Abuse Deterrent Formulations | Opioids With Abuse-Deterrent Properties in Clinical Practice</title>
 
	<link rel="stylesheet" href="css/fonts.css" type="text/css" />
	
    <link rel="stylesheet" href="css/mobile_small.css" type="text/css" media="all and (min-width:100px) and (max-width:320px)"/>
    
    <link rel="stylesheet" href="css/mobile.css" type="text/css" media="all and (min-width:321px) and (max-width:520px)"/>
    
    <link rel="stylesheet" href="css/galaxy.css" type="text/css" media="all and (min-width:521px) and (max-width:767px)"/>
	
    <link rel="stylesheet" href="css/tablet.css" type="text/css" media="all and (min-width:768px) and (max-width:1023px)"/>
    
    <link rel="stylesheet" href="css/desktop.css" type="text/css" media="all and (min-width:1024px) and (max-width:1400px)"/>
	
    <link rel="stylesheet" href="css/large_screen.css" type="text/css" media="all and (min-width:1401px) and (max-width:1700px)"/>
    
    <link rel="stylesheet" href="css/larger_screen.css" type="text/css" media="all and (min-width:1701px) and (max-width:2200px)"/>
    
    <link rel="stylesheet" href="css/largest.css" type="text/css" media="all and (min-width:2201px) and (max-width:4400px)"/>
    
	<link rel="stylesheet" href="css/slidebars.css">
	<script src="js/jquery-1.11.1.min.js" type="text/javascript"></script>
    <script src="js/html5shiv.js" type="text/javascript"></script>
    <script src="js/main.js" type="text/javascript"></script>
    <script src="js/respond.js"></script> 
	<!--[if IE]>
	<script src="http://html5shiv.googlecode.com/svn/trunk/html5.js"></script><![endif]-->
	<!--[if lt IE 9]>
	<script src="http://ie7-js.googlecode.com/svn/version/2.1(beta4)/IE9.js"></script>
	<![endif]-->
 	
</head>
 
<body id="index" class="home">
<header>
	<div class="stop_ad"></div>
	<div class="go_ad"></div>
</header>

<div class="rounded_corners_container">

<!-- NAVIGATION BEGINS -->
<aside class="sb-slidebar sb-left sb-width-custom" data-sb-width="50%">
	<nav class="menu">
    	<ul>
            <li><a href="index.html">Home</a></li>
        	<li><a href="the_challenge.html">The Challenge of Opioid Abuse and Misuse</a></li>
        	<li><a href="types.html">Types of Opioids With Abuse-Deterrent Properties</a></li>
        	<li><a href="clinical_studies.html">Clinical Studies</a></li>
        	<li><a class="activeLink" href="prescribing.html">Opioids With Abuse-Deterrent Properties</a></li>
        	<li><a href="references.html">References</a></li>
			<li><a href="registration.html">Registration</a></li>

        </ul>
    </nav>
</aside>
<!-- NAVIGATION ENDS -->


<section class="main_content_container">

<!-- NAVIGATION BEGINS -->
<aside class="desktop_nav">
	<nav class="menu">
    	<ul>
            <li id="home"><a href="index.html">Home</a></li>
        	<li id="challenge"><a href="the_challenge.html">The Challenge of Opioid Abuse and Misuse</a></li>
        	<li id="types"><a href="types.html">Types of Opioids With Abuse-Deterrent Properties</a></li>
        	<li id="clinical"><a href="clinical_studies.html">Clinical Studies</a></li>
        	<li id="opioids"><a class="activeLink" href="prescribing.html">Opioids With Abuse-Deterrent Properties</a></li>
        	<li id="references"><a href="references.html">References</a></li>
            <li id="registration"><a href="registration.html">Registration</a></li>
        </ul>
    </nav>
</aside>
<!-- NAVIGATION ENDS -->
	<article class="desktop_articles">
    	<div id="showLeftPush"  class="sb-toggle-left"></div>
        <h1>Prescribing Opioid Formulations With Abuse-Deterrent Properties</h1> 
        <p>Before deciding to prescribe an opioid with abuse-deterrent properties for your patients, 
        it is important to consider the fundamentals for prescribing any opioid for the management of pain. 
        Prescribing opioids is an important responsibility, since this class of drugs is associated with the potential 
        for serious adverse events, drug interactions, accidental overdose, addiction, and abuse, misuse, and diversion.<sup><a style="text-decoration:none;"href="references.html">4</a></sup> 
        A full assessment of risks and benefits should include<sup><a style="text-decoration:none; "href="references.html">4</a></sup>: <p>

		<ul class="manipulation" style="color:#72BF44">
        	<li><span style="color:black;">History of substance abuse</span></li>
        	<li><span style="color:black;">Physical exam to assess etiology of chronic pain</span></li>
        	<li><span style="color:black;">Level and quality of pain</span></li>
        	<li><span style="color:black;">Disability</span></li>
        	<li><span style="color:black;">Impact on quality of life</span></li>
        </ul>
        
        <p><a href="the_challenge.html#diversion">Diversion of opioid medications is a serious problem</a>. Even if a patient can be regarded as having a low risk for abuse, 
        it is impossible to rule out that the medications might fall into the wrong hands.<sup><a style="text-decoration:none; " href="references.html">2</a></sup> Considering the high potential for opioid abuse, it is understandable 
        why some groups are taking steps to call for the eradication of all opioids without abuse-deterrent properties, such as the <a href="http://beta.congress.gov/bill/113th-congress/house-bill/486" target="new">Stop Tampering of Prescription 
        Pills (STOPP) Act</a> introduced to Congress in 2013.<sup><a style="text-decoration:none;" href="references.html">5</a></sup> Should this act become law, all new opioid products would be required to be formulated 
        with abuse-deterrent properties, and conventional opioids would be at risk of having their approval withdrawn or suspended.<sup><a style="text-decoration:none;" href="references.html">5</a></sup></p>
        
        <h2><a name="benefit">The benefit of opioids with abuse-deterrent properties</a></h2>
        <p>The development of opioid analgesics with abuse-deterrent properties is intended to help deter the abuse, misuse, and diversion these products are subject to, 
        while ensuring that patients in pain continue to have appropriate access to these important agents.<sup><a style="text-decoration:none;" href="references.html">1</a></sup> Although there is no formulation or technology that can 
        completely prevent the unintended use of opioids,<sup><a style="text-decoration:none;" href="references.html">1</a></sup> the availability of opioid formulations with abuse-deterrent properties is an important advancement toward 
        the goal of providing responsible pain management for those patients who truly need them.<sup><a style="text-decoration:none;" href="references.html">1</a></sup></p>
        
        <span class="anchor"><a name="top" href="#">Back to Top</a></span>
    </article>
</section>

</div>
<footer><a href="legal.html">Terms and conditions</a>  |  <a href="legal.html#privacy">Privacy Policy</a>  |  <a href="sitemap.html">Sitemap</a>  |  <a href="contact_us.html">Contact Us</a>

	<div id="copyright">
		Copyright &copy;2014 Purdue Pharma L.P., Stamford, CT 06901-3431.<br>
		Intended for residents of the United States only.<br>
		Purdue, as used in this site, refers to Purdue Pharma L.P.,<br>
		Purdue Products L.P., and their independent associated U.S. companies.
    </div>

</footer>
<script src="js/slidebars.js"></script>
    <script>
      (function($) {
        $(document).ready(function() {
          $.slidebars();
        });
      }) (jQuery);
	  $("#opioids").addClass("goicons");
    </script>
</body>
</html>